The National Heart, Lung, and Blood Institute (NHLBI) awarded a $977,998.39 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Methodist Hospital Research Institute in Houston, Texas. The grant, titled "VENOUS ETHANOL ABLATION IN ISCHEMIC VENTRICULAR TACHYCARDIA- VELVET TRIAL", aims to evaluate the use of venous ethanol ablation in combination with conventional radiofrequency (RF) ablation for the treatment of ischemic ventricular tachycardia. The R33 phase of the grant, spanning from September 1, 2024 to August 31, 2028, will enroll 156 patients to collect data on the efficacy, safety, and procedural impact of venous ethanol ablation when added to standard catheter ablation. The research will also characterize the VT substrate before and after ablation using advanced multi-modal imaging techniques, including cardiac MRI, venous CT angiograms, and PET scans of adrenergic innervation. This research seeks to validate a novel procedural strategy and provide new insights into the structural determinants of successful VT ablation.
Generated 2/25/25, 3:40 AM